Opening of US Sites for AMPLICITY Pancreatic Cancer Trial

Amplia has announced that two sites in the US have been initiated and will shortly be commencing recruitment activities for the AMPLICITY trial.

The two sites – University of California, Irvine and The Cleveland Clinic – join the two sites already open in Australia at the Epworth Hospital in Melbourne and Genesis Care in Sydney. An additional three US sites will be initiated over the next month as recruitment to the trial continues.

The AMPLICITY trial is investigating narmafotinib, the Company’s best-in-class FAK inhibitor, in combination with the chemotherapy FOLFIRINOX in advanced pancreatic cancer.

Dr Chris Burns, CEO of Amplia, commented:

“These two excellent clinical trial sites in the US help to significantly expand our potential patient base for the AMPLICITY trial, while also contributing to enhancing our presence in the United States both from a clinical and investor perspective. With these two sites, and shortly an additional three sites, we expect to be able to enrol the ongoing study as efficiently as possible. We thank the trial sites and clinical teams for their diligent efforts in completing the pre-trial activities.”

Click to read the ASX release.